OptimizeRx Corporation (OPRX) Return on equity 2016–2025
OptimizeRx Corporation (OPRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
4.0%FY2025 · since FY2016: -19.7% → 4.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 4.0% | +21.2 pp |
| FY2024 | -17.2% | -3.3 pp |
| FY2023 | -13.9% | -4.8 pp |
| FY2022 | -9.1% | -9.4 pp |
| FY2021 | 0.3% | +4.7 pp |
| FY2020 | -4.4% | +2.6 pp |
| FY2019 | -7.0% | -8.2 pp |
| FY2018 | 1.2% | +35.1 pp |
| FY2017 | -33.8% | -14.1 pp |
| FY2016 | -19.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More OPRX financial trends
OPRX RevenueOPRX Net incomeOPRX Net marginOPRX Gross profitOPRX Gross marginOPRX Operating incomeOPRX Operating marginOPRX Operating cash flowOPRX Free cash flowOPRX Capital expendituresOPRX Stock buybacksOPRX Dividends paidOPRX Total assetsOPRX Total liabilitiesOPRX Shareholders’ equityOPRX overview →